← Eichor
Study identifier: NCT06512389 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

Condition: Alcohol Use Disorder  ·  Sponsor: Centre for Addiction and Mental Health

PhasePhase 2
Planned participants36
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.

This description comes directly from the study's public registry record.

Talk to the study team

Kelly Xiao, MSc  ·  416-535-8501  ·  kelly.xiao@camh.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Centre for Addiction and Mental HealthToronto, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06512389